PARP inhibitors for sensitization of alkylation chemotherapy in glioblastoma: Impact of blood-brain barrier and molecular heterogeneity

Shiv K. Gupta, Emily J. Smith, Ann C. Mladek, Shulan Tian, Paul A. Decker, Sani Kizilbash, Gaspar J. Kitange, Jann N Sarkaria

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Prognosis of patients with glioblastoma (GBM) remains dismal despite maximal surgical resection followed by aggressive chemo-radiation therapy. Almost every GBM, regardless of genotype, relapses as aggressive recurrent disease. Sensitization of GBM cells to chemo-radiation is expected to extend survival of patients with GBM by enhancing treatment efficacy. The PARP family of enzymes has a pleiotropic role in DNA repair and metabolism and has emerged as an attractive target for sensitization of cancer cells to genotoxic therapies. However, despite promising results from a number of preclinical studies, progress of clinical trials involving PARP inhibitors (PARPI) has been slower in GBM as compared to other malignancies. Preclinical in vivo studies have uncovered limitations of PARPI-mediated targeting of base excision repair, considered to be the likely mechanism of sensitization for temozolomide (TMZ)-resistant GBM. Nevertheless, PARPI remain a promising sensitizing approach for at least a subset of GBM tumors that are inherently sensitive to TMZ. Our PDX preclinical trial has helped delineate MGMT promoter hyper-methylation as a biomarker of the PARPI veliparib-mediated sensitization. In clinical trials, MGMT promoter hyper-methylation now is being studied as a potential predictive biomarker not only for response to TMZ therapy alone, but also PARPI-mediated sensitization of TMZ therapy. Besides the combination approach being investigated, IDH1/2 mutant gliomas associated with 2-hydroxygluterate (2HG)-mediated homologous recombination (HR) defect may potentially benefit from PARPI monotherapy. In this article, we discuss existing results and provide additional data in support of potential alternative mechanisms of sensitization that would help identify potential biomarkers for PARPI-based therapeutic approaches to GBM.

Original languageEnglish (US)
Article number670
JournalFrontiers in Oncology
Volume9
Issue numberJAN
DOIs
StatePublished - Jan 1 2019

Fingerprint

temozolomide
Alkylation
Glioblastoma
Blood-Brain Barrier
Drug Therapy
Biomarkers
DNA Repair
Methylation
Clinical Trials
Neoplasms
Poly(ADP-ribose) Polymerase Inhibitors
Homologous Recombination
Therapeutics
Glioma
Radiotherapy
Genotype
Radiation
Recurrence
Survival
Enzymes

Keywords

  • Chemo-radiation sensitivity
  • DNA Damage
  • DNA repair activity
  • PARP (poly(ADP-ribose) polymerase
  • Replication stress

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

PARP inhibitors for sensitization of alkylation chemotherapy in glioblastoma : Impact of blood-brain barrier and molecular heterogeneity. / Gupta, Shiv K.; Smith, Emily J.; Mladek, Ann C.; Tian, Shulan; Decker, Paul A.; Kizilbash, Sani; Kitange, Gaspar J.; Sarkaria, Jann N.

In: Frontiers in Oncology, Vol. 9, No. JAN, 670, 01.01.2019.

Research output: Contribution to journalReview article

Gupta, Shiv K. ; Smith, Emily J. ; Mladek, Ann C. ; Tian, Shulan ; Decker, Paul A. ; Kizilbash, Sani ; Kitange, Gaspar J. ; Sarkaria, Jann N. / PARP inhibitors for sensitization of alkylation chemotherapy in glioblastoma : Impact of blood-brain barrier and molecular heterogeneity. In: Frontiers in Oncology. 2019 ; Vol. 9, No. JAN.
@article{d4c45dd5ac154eaa9cf4edbc6c584f9a,
title = "PARP inhibitors for sensitization of alkylation chemotherapy in glioblastoma: Impact of blood-brain barrier and molecular heterogeneity",
abstract = "Prognosis of patients with glioblastoma (GBM) remains dismal despite maximal surgical resection followed by aggressive chemo-radiation therapy. Almost every GBM, regardless of genotype, relapses as aggressive recurrent disease. Sensitization of GBM cells to chemo-radiation is expected to extend survival of patients with GBM by enhancing treatment efficacy. The PARP family of enzymes has a pleiotropic role in DNA repair and metabolism and has emerged as an attractive target for sensitization of cancer cells to genotoxic therapies. However, despite promising results from a number of preclinical studies, progress of clinical trials involving PARP inhibitors (PARPI) has been slower in GBM as compared to other malignancies. Preclinical in vivo studies have uncovered limitations of PARPI-mediated targeting of base excision repair, considered to be the likely mechanism of sensitization for temozolomide (TMZ)-resistant GBM. Nevertheless, PARPI remain a promising sensitizing approach for at least a subset of GBM tumors that are inherently sensitive to TMZ. Our PDX preclinical trial has helped delineate MGMT promoter hyper-methylation as a biomarker of the PARPI veliparib-mediated sensitization. In clinical trials, MGMT promoter hyper-methylation now is being studied as a potential predictive biomarker not only for response to TMZ therapy alone, but also PARPI-mediated sensitization of TMZ therapy. Besides the combination approach being investigated, IDH1/2 mutant gliomas associated with 2-hydroxygluterate (2HG)-mediated homologous recombination (HR) defect may potentially benefit from PARPI monotherapy. In this article, we discuss existing results and provide additional data in support of potential alternative mechanisms of sensitization that would help identify potential biomarkers for PARPI-based therapeutic approaches to GBM.",
keywords = "Chemo-radiation sensitivity, DNA Damage, DNA repair activity, PARP (poly(ADP-ribose) polymerase, Replication stress",
author = "Gupta, {Shiv K.} and Smith, {Emily J.} and Mladek, {Ann C.} and Shulan Tian and Decker, {Paul A.} and Sani Kizilbash and Kitange, {Gaspar J.} and Sarkaria, {Jann N}",
year = "2019",
month = "1",
day = "1",
doi = "10.3389/fonc.2018.00670",
language = "English (US)",
volume = "9",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "JAN",

}

TY - JOUR

T1 - PARP inhibitors for sensitization of alkylation chemotherapy in glioblastoma

T2 - Impact of blood-brain barrier and molecular heterogeneity

AU - Gupta, Shiv K.

AU - Smith, Emily J.

AU - Mladek, Ann C.

AU - Tian, Shulan

AU - Decker, Paul A.

AU - Kizilbash, Sani

AU - Kitange, Gaspar J.

AU - Sarkaria, Jann N

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Prognosis of patients with glioblastoma (GBM) remains dismal despite maximal surgical resection followed by aggressive chemo-radiation therapy. Almost every GBM, regardless of genotype, relapses as aggressive recurrent disease. Sensitization of GBM cells to chemo-radiation is expected to extend survival of patients with GBM by enhancing treatment efficacy. The PARP family of enzymes has a pleiotropic role in DNA repair and metabolism and has emerged as an attractive target for sensitization of cancer cells to genotoxic therapies. However, despite promising results from a number of preclinical studies, progress of clinical trials involving PARP inhibitors (PARPI) has been slower in GBM as compared to other malignancies. Preclinical in vivo studies have uncovered limitations of PARPI-mediated targeting of base excision repair, considered to be the likely mechanism of sensitization for temozolomide (TMZ)-resistant GBM. Nevertheless, PARPI remain a promising sensitizing approach for at least a subset of GBM tumors that are inherently sensitive to TMZ. Our PDX preclinical trial has helped delineate MGMT promoter hyper-methylation as a biomarker of the PARPI veliparib-mediated sensitization. In clinical trials, MGMT promoter hyper-methylation now is being studied as a potential predictive biomarker not only for response to TMZ therapy alone, but also PARPI-mediated sensitization of TMZ therapy. Besides the combination approach being investigated, IDH1/2 mutant gliomas associated with 2-hydroxygluterate (2HG)-mediated homologous recombination (HR) defect may potentially benefit from PARPI monotherapy. In this article, we discuss existing results and provide additional data in support of potential alternative mechanisms of sensitization that would help identify potential biomarkers for PARPI-based therapeutic approaches to GBM.

AB - Prognosis of patients with glioblastoma (GBM) remains dismal despite maximal surgical resection followed by aggressive chemo-radiation therapy. Almost every GBM, regardless of genotype, relapses as aggressive recurrent disease. Sensitization of GBM cells to chemo-radiation is expected to extend survival of patients with GBM by enhancing treatment efficacy. The PARP family of enzymes has a pleiotropic role in DNA repair and metabolism and has emerged as an attractive target for sensitization of cancer cells to genotoxic therapies. However, despite promising results from a number of preclinical studies, progress of clinical trials involving PARP inhibitors (PARPI) has been slower in GBM as compared to other malignancies. Preclinical in vivo studies have uncovered limitations of PARPI-mediated targeting of base excision repair, considered to be the likely mechanism of sensitization for temozolomide (TMZ)-resistant GBM. Nevertheless, PARPI remain a promising sensitizing approach for at least a subset of GBM tumors that are inherently sensitive to TMZ. Our PDX preclinical trial has helped delineate MGMT promoter hyper-methylation as a biomarker of the PARPI veliparib-mediated sensitization. In clinical trials, MGMT promoter hyper-methylation now is being studied as a potential predictive biomarker not only for response to TMZ therapy alone, but also PARPI-mediated sensitization of TMZ therapy. Besides the combination approach being investigated, IDH1/2 mutant gliomas associated with 2-hydroxygluterate (2HG)-mediated homologous recombination (HR) defect may potentially benefit from PARPI monotherapy. In this article, we discuss existing results and provide additional data in support of potential alternative mechanisms of sensitization that would help identify potential biomarkers for PARPI-based therapeutic approaches to GBM.

KW - Chemo-radiation sensitivity

KW - DNA Damage

KW - DNA repair activity

KW - PARP (poly(ADP-ribose) polymerase

KW - Replication stress

UR - http://www.scopus.com/inward/record.url?scp=85062275430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062275430&partnerID=8YFLogxK

U2 - 10.3389/fonc.2018.00670

DO - 10.3389/fonc.2018.00670

M3 - Review article

AN - SCOPUS:85062275430

VL - 9

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - JAN

M1 - 670

ER -